RENAL EFFECTS OF THE SULFUR-CONTAINING AMINOACID DERIVATIVES (ADEMETIONINE, TAURIN AND GLUTATHIONE) IN CONDITIONALLY HEALTHY ANIMALS

V. M. Drachuk, I. I. Zamorskii, T. S. Shchudrova, Ol. M. Goroshko

Higher State Educational Establishment of Ukraine “Bukovinian State Medical University”

Derivatives of sulfur-containing aminoacids (ademetionin, taurine and glutathione) selected for the experimental studies are used in various fields of practical medicine due to their multifaceted pleiotropic effects. The study of their renal effects in the conditions of the physiological norm makes it possible to expand and supplement their pharmacological characteristics, and forms the basis for further study of the nephroprotective potential in renal pathology.

Aim. To study the effect of sulfur-containing amino acid derivatives (ademetionine, taurine and glutathione) on the morphofunctional state of the rat kidneys in the daily administration for 7 days.

Materials and methods. The experiments were performed on mature non-linear white rats weighing 130-180 g. Animals were divided into 4 groups (n = 7): group I – intact control, group II – animals which were given ademetionine (“Geptral”, “Abbott Spa”, Italy) in the dose of 20 mg/kg, group III – animals received taurine (“Sigma-Aldrich”, USA) in the dose of 100 mg/kg, group IV – animals received glutathione (“TAD 600”, “Biomedica Foscama”, Italy) in the dose of 30 mg/kg. All drugs were injected intramuscularly for 7 days.

Results. The study of the renal effects of the sulfur-containing amino acid derivatives (SAD) under research in the daily administration for 7 days to conditionally healthy animals showed that these drugs had a weak diuretic effect, which was probably due to a decreased tubular reabsorption of water without significant changes in the glomerular filtration rate. Besides, the use of ademetionine resulted in a slight reduction of azotemia. There was not any significant change in the acid regulatory kidney function under the effect of SAD. Administration of ademetionine, taurine and glutathione resulted in a significant decrease in proteinuria, which was probably caused by the effect on the processes of protein reabsorption. The effect on the ion regulatory kidney function upon the course of SAD administration was characterized by an increase in urinary sodium excretion against the background of decreased relative sodium reabsorption, which was accompanied by intensification of distal transport of sodium ions due to the activation of the tubular-tubular balance.

Conclusions. According to the data obtained the 7-day administration of ademetionine, taurine and glutathione to conditionally healthy animals moderately affects the processes of glomerular filtration and tubular transport in nephrons, which results in a slight increase in diuresis along with preservation of the renal mechanisms of autoregulation and the absence of histopathological changes in the kidneys.

Key words: renal effects; ademetionine; taurine; glutathione
В. М. Дрчук, І. І. Заморський, Т. С. Щудрова, А. М. Горошко

Высше государственное учебное заведение Украины «Буковинский государственный медицинский университет»

Ренальные эффекты производных серосодержащих аминокислот (адеметионина, таурина и глутатиона) при применении у условно здоровых животных

Изучены для экспериментального исследования производные серосодержащих аминокислот (адеметионин, таурин и глутатион) благодаря своим многогранным плейотропным эффектам применяются в различных областях практической медицины. Исследование их ренальных эффектов и условий физиологической нормы дает возможность расширить и дополнить их фармакологическую характеристику, создает основу для дальнейшего изучения нефропротекторного потенциала при патологии почек.

Цель. Исследование влияния производных серосодержащих аминокислот (адеметионина, таурина и глутатиона) на морфофункциональное состояние почек крыс после курсового введения препаратов.

Материалы и методы. Исследование ренальных эффектов производных серосодержащих аминокислот (адеметионина, таурина и глутатиона) проведено на половозрелых нелинейных белых крысах массой 130-180 г. Животные были распределены на 4 группы (n = 7): I группа – интактный контроль, II группа – группа животных, которым вводили адеметионин («Гептрал», «Abbott SpA», Италия) в дозе 20 мг/кг, III – группа животных, которым вводили таурин (Sigma-Aldrich, USA) в дозе 100 мг/кг, IV – группа животных, которым вводили глутатион («ТАД 600», «Biomedica Foscana», Италия) в дозе 30 мг/кг. Все препараты вводили внутримышечно в течение 7-ми дней.

Результаты. Изучение ренальных эффектов исследуемых производных серосодержащих аминокислот (ПСА) при 7-дневном введении условно здоровым животным позволило установить, что исследуемые препараты оказывают слабое диуретическое действие, которое вероятно обусловлено уменьшением канальцевой реабсорбции воды при отсутствии достоверных изменений скорости клубочковой фильтрации. При этом из исследуемых препаратов только адеметионин оказывает незначительное гипотензивное действие. При исследовании состояния кислоторегулирующей функции почек не выявлено значительных изменений. В группах животных, которым вводили адеметионин, таурин и глутатион, наблюдается достоверное уменьшение проницаемости, обусловленное влиянием на процессы реабсорбции белка. При курсовом введении ПСА влияние на ионорегулирующую функцию почек характеризовалось ростом экскреции на фоне уменьшения относительной реабсорбции ионов натрия, что сопровождалось усилением дистального транспорта ионов натрия за счет активации канальцево-канальцевого баланса. По данным морфологического исследования патологических гистоструктурных изменений ткани почек под влиянием препаратов не выявлено, что свидетельствует об отсутствии нефротоксических свойств исследуемых ПСА.

Выводы. На основании проведенного эксперимента можно сделать вывод, что при 7-дневном введении условно здоровым животным исследуемые препараты адеметионина, таурина и глутатиона незначительно усиливают диурез и оказывают слабое влияние на процессы клубочковой фильтрации и канальцевого транспорта в нефронах при сохранении внутрипочечных механизмов авторегуляции и отсутствии патологических изменений гистоструктуры почек.

Ключевые слова: ренальный эффект; адеметионин; таурин; глутатион

To date, in spite of the achievements of the pharmaceutical industry, the problem of prevention and treatment of acute kidney injury (AKI), which prevalence reaches 31 % and the mortality rate exceeds 80 % of patients, remains an urgent and unsolved issue of modern nephrology [1]. According to the literature data the key link in the pathogenesis of the renal pathology is development of the oxidative stress, which is characterized by the prooxidant-antioxidant imbalance [2] and involves a shift of the redox equilibrium towards free radical oxidation with formation of lipid and protein peroxides [3]. Consequently, the promising direction is the use of nephroprotectors with the aim of strengthening the antioxidant defense, and inducing the membrane protective and cytotoxic protective mechanisms. It is known that sulfur-containing amino acids presented at the pharmaceutical market of Ukraine by such drugs as ademetionine, taurine and glutathione possess these properties.

Ademetionine is an active sulfur-containing metabolite of methionine, a natural antioxidant and antidepressant. Endogenous ademetionine is involved in transmethylation reactions, promoting the synthesis of phosphatidylycholine in the cell membrane and providing the membrane protective action [4]. In the transsulfuration reactions it acts as a precursor of sulfur compounds (cysteine, taurine and glutathione); in transmethylation reactions it par-
ne, adrenaline, norepinephrine) [5, 6]. As a medicine ademetionine belongs to the group of hepatoprotectors, but due to its pleiotropic properties it possesses the cytoprotective, anti-inflammatory, analgesic, anti-depressant, neuroprotective and antiepileptic effect [7].

Glutathione acts as the most powerful antioxidant due to the reactivity of SH-group [8]. The system of glutathione plays an important role in maintaining the thiol-disulphide balance in tissues, which is essential for implementation of such processes as the functioning of membrane structures and cytoskeleton, cell division [9-11]. As a medicine it is represented at the market in a form of sodium salt of recovered glutathione, and is used to prevent nephrotoxicity and hepatotoxicity of cisplatin, as well as in acute and chronic hepatitis, liver cirrhosis, etc. [12].

Taurine is a sulfur-containing amino acid that participates in a wide range of physiological processes, such as conjugation of bile acids, which prevents cholestasis, and stabilization of photoreceptors cells of the eye retina. Taurine is one of the main cell regulators due to its effect on the transport processes of sodium and chloride ions, it acts as a neuromodulator in the central nervous system, has potent anti-inflammatory, antioxidant, and detoxifying properties, possesses antiarrhythmic and inotropic effects [13-17]. Taurine is produced in a form of one-component eye drops and biologically active additives [18].

Considering the pleiotropic effects of sulfur-containing amino acid derivatives (SAD) – ademetionine, taurine and glutathione allowing their use in different pathologies their renal effects in physiological conditions are of special interest. It may complement the characteristics of the drugs studied and provide the background for further study of their nephroprotective potential in different kidney pathologies.

The aim of the study was to determine the effects of SAD on the morphofunctional state of the rat kidneys in the daily administration for 7 days.

Materials and methods

The experiments were performed on mature non-linear white rats weighing 130-180 g, maintained in the vivarium with the constant temperature and humidity, and with free access to water and food. Animals were divided into 4 groups (n = 7): group I – intact control, group II – animals which were given ademetionine (“Geptral”, “Abbott SpA”, Italy) in the dose of 20 mg/kg, group III – animals received taurine (“Sigma-Aldrich”, USA) in the dose of 100 mg/kg, group IV – animals received glutathione (“TAD 600”, “Biomedica Foscama”, Italy) in the dose of 30 mg/kg. All drugs were injected intramuscularly for 7 days. The studies were conducted in accordance with the provisions of the “European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes” [19].

The functional status of the rat kidneys was assessed on day 8. Urine was collected for 2 h under the conditions of induced water load (enteral administration of drinking water heated to 37°C in the amount of 5 % of the body weight using an intragastric tube) by the indices of diuresis, glomerular filtration rate (GFR), urine protein level and excretion, urine pH, excretion of titrated acids and ammonium ions, reabsorption and urine excretion of sodium and potassium ions [20]. The morphological examination of kidney histological sections was performed by staining the samples with hematoxylin and eosin. The preparations were assessed using light microscopy and photographed. Documentation of the pathological processes was performed by the computer morphometry of objects using “VideoTest – Razmer 5.0” computer software (Russian Federation). The statistical analysis of the data was performed using SPSS 17.0 software. All data are presented as a mean ± standard error of the mean (M±m). A character of distribution within the group was determined using Kolmogorov-Smirnov test. Estimation of the differences between the samples was conducted using parametric Student’s t-test (for normal distribution) and nonparametric Mann-Whitney U test (when the assumptions of the t-test were not met). The critical level of significance was accepted at p<0.05.

Results and discussion

The 7-day administration of ademetionine resulted in some changes in the functional state of kidneys (Table). In the experimental group II an increase in diuresis by 15.9 % along with a significant decrease in water reabsorption by 1.1 % was observed, while there were no changes in GFR compared to the control group. The hypoazotemic effect of ademetionine was also found, it was manifested by a decrease in the plasma creatinine level by 19.9 % compared to the control group. The dosage regimen of the drug was effective in reducing proteinuria: the urine protein level decreased by 1.3 times, urine protein excretion was accordingly decreased compared to the control group. Ademetionine had no significant effect on the acid-regulatory kidney function: there was a tendency towards an increase in the urine pH and preservation of titrated acids and excretion of ammonium ions at the control level. Ademetionine demonstrated the following effect on the ion-regulatory kidney function: there was a significant increase in the excretion of sodium ions with urine against the background of a decrease in relative reabsorption of sodium ions. The correlation between GFR and absolute reabsorption of sodium ions (r = 0.96),
The effect of sulfur-containing aminoacid derivatives (ademetionine, taurine and glutathione) on the functional state of kidneys of conditionally healthy rats (M±m, n=7)

| Index                                      | Intact control | Ademetionine (20 mg/kg) | Taurine (100 mg/kg) | Glutathione (30 mg/kg) |
|--------------------------------------------|----------------|-------------------------|---------------------|------------------------|
| Diuresis, ml/2 h×100 g                    | 3.78±0.19      | 4.38±0.15*              | 4.89±0.13**         | 4.60±0.09**            |
| Plasma creatinine, μmol/l                 | 59.00±2.23     | 49.22±1.83*             | 53.61±2.26          | 61.53±1.90             |
| Glomerular filtration rate, μl/min×100 g  | 536.6±26.03    | 545.54±36.31            | 593.35±49.61        | 573.79±23.90           |
| Reabsorption of water, %                  | 99.29±0.02     | 98.22±0.02**            | 97.15±0.06**        | 97.19±0.04**           |
| Urine protein, g/l                        | 0.022±0.001    | 0.017±0.001**           | 0.011±0.001**       | 0.015±0.001**          |
| Urine protein excretion, mg/100 μl        | 0.083±0.002    | 0.072±0.001**           | 0.053±0.001**       | 0.068±0.001**          |
| Urine pH                                   | 7.07±0.11      | 7.35±0.07               | 7.24±0.10           | 7.16±0.12              |
| Titrated acids excretion, μmol/2 h         | 27.30±1.35     | 26.68±1.63              | 24.76±1.36          | 22.44±1.90             |
| Ammonium ions excretion, μmol/2 h          | 33.41±2.19     | 37.56±2.63              | 31.33±2.04          | 31.20±1.83             |
| Plasma Na+, mmol/l                        | 135.36±4.45    | 142.50±4.53             | 136.07±2.37         | 133.57±4.75            |
| Excretion of Na+, μmol/2 h                | 1.93±0.09      | 3.76±0.21**             | 3.28±0.17**         | 3.62±0.50**            |
| Absolute Na+ reabsorption, μmol/min       | 80.83±5.19     | 93.42±7.19              | 97.02±8.81          | 91.73±4.49             |
| Relative Na+ reabsorption, %              | 98.37±0.10     | 96.86±0.18**            | 97.26±0.14**        | 96.99±0.42**           |
| Proximal transport of Na+, mmol/min       | 9.23±0.60      | 10.62±0.84              | 10.98±1.04          | 10.40±0.53             |
| Distal transport of Na+, μmol/min         | 470.98±27.70   | 593.38±33.61*           | 662.46±24.37**      | 609.99±24.68**         |
| Plasma K+, mmol/l                         | 5.18±0.25      | 5.71±0.51               | 5.21±0.28           | 5.36±0.44              |
| Excretion of K+, μmol/2 h                 | 23.15±1.42     | 23.26±0.96              | 18.25±1.87          | 21.25±1.42             |

Note. Significant differences compared to the intact control group – * (p<0.05), ** (p<0.01).

and between GFR and proximal sodium transport (r = 0.86) confirms the maintenance of the glomerular-tubular balance. In addition, under the effect of the drug there was an increase in distal sodium transport by 1.3 times along with a tendency towards a reduction of proximal sodium transport, indicating the activation of tubular-tubular balance (r = -0.83). At the same time, taurine did not affect the transport of potassium ions.

The study of the renal effects of taurine revealed a slight diuretic effect, which was confirmed by a significant increase in diuresis by 29.4 % compared to the control group (Table). The use of taurine did not affect the plasma creatinine level. There was a tendency towards an increase in GFR along with a decrease in water reabsorption compared to the intact animals. At the same time, administration of taurine resulted in the most pronounced effect on protein transport among the drugs studied: there was a 2-fold decrease in the urine protein level and reduction of protein excretion by 1.6 times compared to the control group. There were no significant changes in the acid-regulatory kidney function after taurine administration for 7 days. In the ion-regulatory kidney function a significant increase (by 1.7 times) in sodium excretion was observed due to an increase in diuresis and decrease in relative sodium reabsorption. Theglomerular-tubular balance was maintained when administrating taurine, and it was confirmed by the correlation between GFR and absolute reabsorption of sodium ions (r = 1), GFR and proximal transport of sodium ions (r = 0.96). The tubular-tubular balance was characterized by an increase in distal transport of sodium ions (1.4 times) in the absence of changes in proximal sodium transport and characterized by a reverse correlation between proximal and distal transport of sodium ions (r = -0.89). Like ademetionine, taurine did not affect the processes of potassium transport.

When studying the effect of glutathione on the excretory function of the rat kidney an increase in diuresis by 21.7 % was revealed due to a decrease in tubular reabsorption of water in the absence of significant changes in GFR and the plasma creatinine level (Table). Glutathione also showed a pronounced effect on the tubular transport of protein: the urine protein level was decreased by 1.5 times, protein excretion – by 1.2 times compared to the control animals. Under the effect of glutathione a decrease in titrated acid excretion by 17.8 % was observed without significant changes in the urine pH compared to the intact animals. Although the index of absolute sodium reabsorption did not differ significantly from the control level, the relative sodium reabsorption decreased by 1.4 %, which led to a 1.3-fold increase in the distal transport of sodium by the mechanism of the tubular-tubular balance activation. The glomerular-tubular balance was confirmed by the correlation between GFR and the absolute sodium reabsorption (r = 0.86), as well as between GFR and proximal transport of sodium (r = 0.96). The functioning of the tubular-tubular ba-
lance was expressed in the negative correlation between proximal and distal reabsorption of sodium (r = -0.93). There were no changes in the plasma potassium level and its excretion.

The histological examination of the kidneys of rats received ademetionine (Fig. 1A) revealed signs of reversible hydropic swelling in 5% of proximal tubular epitheliocytes mostly in the juxtaglomerular zone within the physiological range. These changes may be due to the effect of ademetionine on the processes of water, protein, sodium and potassium transport in proximal tubules.

In group of rats which were taken taurine during the morphological examination there were no histopathological changes in the renal tissue, confirming the absence of nephrotoxic effects (Fig. 1B). According to the results of the morphological study the 7-day administration of glutathione did not cause any changes in the morphological organization of the renal tissue (Fig. 1C): glomeruli were of normal structure and size, the interstitium and epithelium of the proximal and distal tubules were without pathological changes, lumens of tubules were free.

The study of the renal effects of SAD in the daily administration for 7 days to conditionally healthy animals revealed a weak diuretic effect, which was probably due to a decreased tubular reabsorption of water without significant changes in GFR. Thus, the use of ademetionine resulted in a slight reduction of azotemia. The use of SAD did not cause any significant effect on the acid regulatory kidney function. Administration of ademetionine, taurine and glutathione resulted in a significant reduction of proteinuria, which was probably caused by the effect on the processes of protein reabsorption. The effect on the ion regulatory kidney function during the course of SAD administration was characterized by an increase in urinary sodium excretion against the background of decreased relative sodium reabsorption, which was accompanied by intensification of distal transport of sodium ions due to the activation of the tubular-tubular balance. The morphological examination did not reveal any histopathological changes in the renal tissue, confirming the absence of nephrotoxicity of the SAD studied.

CONCLUSIONS

According to the results of the experiment conducted daily administration of the sulfur-containing amino acids derivatives (ademetionine, taurine and glutathione) for 7 days to conditionally healthy animals causes a weak diuretic effect with little impact on the processes of glomerular filtration and tubular transport in nephrons, accompanied with maintenance of the renal mechanisms of autoregulation, and the absence of histopathological changes in the kidneys.

Conflict of interests: authors have no conflict of interests to declare.

References

1. Острое повреждение почек: современный взгляд на проблему / Ж. Д. Семидоцкая, И. А. Чернякова, Е. Н. Пионова, Н. С. Трифонова // Східноєвропейський журн. внутрішньої та сімейної медицини. – 2017. – Т. 1. – С. 10–16.

2. Dennis, J. M. Protective Role for Antioxidants in Acute Kidney Disease / J. M. Dennis, P. K. Witting // Nutrients. – 2017. – № 9 (7). – P. 718. https://doi.org/10.3390/nu9070718

3. Oxidant mechanisms in renal injury and disease / B. B. Ratliff, W. Abdulmahdi, R. Pawar, M. S. Wolin // Antioxid. Redox Signal. – 2016. – № 25. – P. 119–146. https://doi.org/10.1089/ars.2016.6665

4. Юрьев, К. Л. Гептрал (адеметионин) – гепатопротектор и антидепрессант / К. Л. Юрьев // Укр. мед. часопис. – 2012. – № 1 (87). – С. 10–16.

5. Звягицева, Т. Д. Роль аденометионина в развитии и прогрессировании хронических заболеваний печени / Т. Д. Звягицева, А. И. Чернобай, С. В. Глущенко // Укр. мед. часопис. – 2014. – № 3 (101). – С. 56–59.

6. Anstee, Q. M. S-adenosylmethionine (SAMe) therapy in liver disease: are view of current eviden ceand clinical utility / Q. M. Anstee, C. P. Day // J. Hepatol. – 2012. – Vol. 57 (5). – P. 1097–1109. https://doi.org/10.1016/j.jhep.2012.04.041

7. Гептрал, инструкція, застосування препарату [Електронний ресурс]. – Режим доступу: http://mozdocs.kiev.ua/likivi ew.php?id=31805.

8. Role of Glutathione in Cancer Progression and Chemoresistant / N. Traverso, R. Ricciarelli, M. Nitti et al. // Oxid. Med. Cell Longev. – 2013. – № 2013. – P. 1–10. https://doi.org/10.1155/2013/972913

Fig. 1. A photomicrograph of the kidney cortex section of the rat received ademetionine, 20 mg/kg (А), taurine, 100 mg/kg (Б), glutathione, 30 mg/kg (С). Staining with haematoxylin and eosin. 100x magnification.
References

1. Semidotkaia, Zh. D., Cherniakova, I. A., Pionova, E. N., Trifonova, N. S. (2017). *East European Journal of Internal and Family Medicine*, 1, 10–16.

2. Dennis, J. M., Witting, P. K. (2017). Protective Role for Antioxidants in Acute Kidney Disease. *Nutrients*, 9(7), 718. https://doi.org/10.3390/nu9070718

3. Rattiff, B. B., Abdulmahdi, W., Pawar, R., & Wolin, M. S. (2016). Oxidant Mechanisms in Renal Injury and Disease. *Antioxidants & Redox Signaling*, 25(3), 119–146. https://doi.org/10.1089/ars.2016.6665

4. Yurev, K. L. (2012). *Ukrainskiy medychnyi chasopys, 1* (87), 10–16.

5. Zvialyntseva, T. D., Chernobai, A. Y., Hlushchenko, S. V. (2014). *Ukrainskiy medychnyi chasopys, 3* (101), 56–59.

6. Anstee, Q. M., & Day, C. P. (2012). S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. *Journal of Hepatology*, 57(5), 1097–1109. https://doi.org/10.1016/j.jhep.2012.04.041

7. Gepral instruktsiya, zastosuvannia preparatu. (n.d.). Available at: http://mozdocs.kiev.ua/lkiview.php?id=31805

8. Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., … Domenicotti, C. (2013). Role of Glutathione in Cancer Progression and Chemoresistance. *Oxidative Medicine and Cellular Longevity*, 2013, 1–10. https://doi.org/10.1051/2013972913

9. Saliga, N. O. (2013). *Ukrains’kij biofarmacevtichniy Jurnal, 85* (4), 40–47.

10. Forman, H. J., Zhang, H., & Rinna, A. (2009). Glutathione: Overview of its protective roles, measurement, and biosynthesis. *Molecular Aspects of Medicine*, 30(1-2), 1–12. https://doi.org/10.1016/j.mam.2008.08.006

11. Luschchak, V. I. (2012). Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions. *Journal of Amino Acids*, 2012, 1–26. https://doi.org/10.1155/2012/736837

12. Hepaval. (n.d.). Available at: https://compendium.com.ua/info/220085/gepaval/

13. Ostapiv, R. D., Kystsiv, O. S., Manko, V. V. (2015). *Visnyk Lvivskoho universytetu serii Biohohiia, 69*, 247–255.

14. Lambert, I. H., Kristensen, D. M., Holm, J. B., & Mortensen, O. H. (2014). Physiological role of taurine – from organism to organelle. *Acta Physiologica*, 213(1), 191–212. https://doi.org/10.1111/apha.12365

15. Yan-Jun, Xu., S. A. Amarjit, S. T. Paramjit, S. D. Naranjan // *Exp. Clin. Cardiol*. – 2008. – № 13 (2). – Р. 57–65.

16. Kamshy, N. V., Spravochnik po kliniko-biokhimicheskim issledovaniam i laboratornoi diagnostike, (3-edition). Moscow: «MEDpressinform», 2009. – 896 c.

9. Салига, Н. О. Активність глутатіонової системи антиоксидантного захисту в щурів за дії L-глутамінової кислоти / H. O. Saliga // Укр. біохім. журн. – 2013. – № 85 (4). – С. 40–47.

10. Forman, H. J. Glutathione: Overview of its protective roles, measurement, and biosynthesis / H. J. Forman, H. Zhang, A. Rinna // Mol. Aspects Med. - 2009. – Vol. 30 (1-2). – P.1-12. https://doi.org/10.1016/j.mam.2008.08.006

11. Luschchak, V. I. Glutathione Homeostasis and Functions: Potential Targets for Medical / V. I. Luschchak // Interventions J. of Amino Acids. – 2012. – P. 26. https://doi.org/10.1155/2012/736837

12. Гепавал [Електронний ресурс] // Компендиум – Лекарственные препараты. – Режим доступу: https://compendium.com.ua/info/220085/gepaval/
